Vivos Therapeutics (VVOS) Q2 2026 earnings summary

Executive summary

• Revenue grew 35% year-over-year to $5.2 million in Q2 2026, driven by service revenue from the SCN acquisition, new treatment centers, and expanded facilities.

• Strategic pivot to a service-based, medical provider-focused model, including SCN acquisition, AIM Detroit formation, and new referral/service initiatives.

• Net loss widened to $5.5 million for Q2 2026 and $13.3 million for the first half of 2026, reflecting higher operating expenses and interest costs.

• Cash and cash equivalents were $1.8 million as of June 30, 2026, insufficient to fund operations for the next twelve months, raising substantial doubt about going concern status.

• Operational improvements, including AI-enabled software conversion and new partnerships, contributed to higher patient volumes and revenue.

Financial highlights

• Q2 2026 revenue increased by $1.3 million (35%) to $5.2 million year-over-year; six-month revenue up 51% to $10.3 million.

• Gross margin improved to 57% in Q2 2026 (from 55% in Q2 2025); six-month gross margin rose to 58% (from 53%).

• Operating loss for Q2 2026 was $4.8 million; net loss per share was $(0.31) for Q2 2026.

• General and administrative/operating expenses rose to $7.8 million in Q2 2026, reflecting higher salaries, SCN integration, and new center costs.

• Cash and equivalents: $1.8 million as of June 30, 2026; total liabilities: $28.1 million; accumulated deficit: $138.5 million.

Outlook and guidance

• Management expects recurring revenue streams from remote patient monitoring, CPAP, and EEG/insomnia programs to accelerate in late 2026 and 2027.

• Revenue growth anticipated from SCN acquisition, new partnerships, and further strategic alliances, though the new model is unproven.

• Cardiology partnerships in Arizona and Florida require $800,000–$1 million CapEx each, with revenue expected to begin in Q1–Q2 2027.

• Positive cash flow targeted by late 2026 or early 2027, with significant EBITDA projected for 2027.

• Additional financing is required to sustain operations and maintain Nasdaq compliance; cost-saving measures have been implemented.